Scrip Asks… What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking
January 9, 2026
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.